scholarly journals Urinary symptoms and the neurological features of bladder dysfunction in multiple sclerosis.

1993 ◽  
Vol 56 (3) ◽  
pp. 245-250 ◽  
Author(s):  
C D Betts ◽  
M T D'Mellow ◽  
C J Fowler
2021 ◽  
Vol 5 (Supplement_1) ◽  
pp. 639-640
Author(s):  
Ramalakshmi Ramasamy ◽  
Cara Hardy ◽  
Stephen Crocker ◽  
Phillip Smith

Abstract Multiple sclerosis (MS) is a chronic inflammatory demyelinating disease of the central nervous system (CNS). Of note, over 80% of MS patients have urinary symptoms as one of their earliest symptoms. Since MS patients often live into older age, urinary incontinence and retention are significant problems affecting their quality of life. Although several studies show that inflammatory-demyelinating animal models of MS develop bladder dysfunction, the confounding influence of systemic inflammation in these models limits potential interpretation on the contribution of CNS-myelination to bladder dysfunction. We sought to address this knowledge gap using the cuprizone model of demyelination and remyelination. C57Bl/6 mice were treated with dietary cuprizone (0.2%w/w) for four weeks to induce demyelination. One group was allowed four additional weeks for recovery and remyelination. We performed voiding spot assay (VSA), urethane-anesthetized cystometry, and CNS-histology to assess demyelination-induced differences in urinary performance. We observed that cortical demyelination causes significant aberrance in voiding behavior (conscious cortical control) characterized by increased micturition frequency and reduced volume per micturition. Interestingly, remyelination restored healthy bladder function. However, there were no significant changes in the cystometric parameters (brainstem reflex) between the treatment groups. While MS is not classically considered a disease of aging, extending the longevity of these patients has not been reciprocated with improved treatments for their most-bothersome conditions, notably urinary symptoms that persist throughout life. Our data represent a novel compelling connection and strong correlation between CNS-myelination and cortical control of bladder function, which has potential implications in MS, aging, and aging-associated neurological disorders.


2013 ◽  
Vol 3 (1) ◽  
Author(s):  
Hiromitsu Negoro ◽  
Sarah E. Lutz ◽  
Louis S. Liou ◽  
Akihiro Kanematsu ◽  
Osamu Ogawa ◽  
...  

2020 ◽  
Vol 3 ◽  
pp. 66
Author(s):  
Hawra B. Al Dandan ◽  
Rose Galvin ◽  
Katie Robinson ◽  
Dorren McClurg ◽  
Susan Coote

Background: Neurogenic lower urinary tract dysfunction (NLUTD) is common among people with multiple sclerosis (MS) with a pooled prevalence of 68.41% using self-report measures and 63.95% using urodynamic studies. Transcutaneous tibial nerve stimulation (TTNS) is a non-invasive option to manage bladder storage symptoms; however, the potential efficacy of TTNS among people with MS is based on a small number of studies with the absence of high-quality evidence relating to efficacy, and lack of clarity of the optimal electrical stimulation parameters and frequency, duration and number of treatment sessions. This study aims to assess whether TTNS is feasible and acceptable as a treatment for bladder storage symptoms in people with MS. Methods: We will use a single-arm experimental study to explore the feasibility and acceptability of TTNS in the treatment of bladder storage symptoms in MS. The CONSORT extension for pilot and feasibility studies will be followed to standardise the conduct and reporting of the study. The recruitment plan is twofold: 1) Open recruitment for people with MS through MS Ireland’s communication channels; 2) recruitment from a convenience sample of people with MS who have previously participated in a qualitative interview study of urinary symptoms. We will assess recruitment/retention rates, the urinary symptoms changes and the effect on quality of life pre and post intervention using ICIQ-OAB, 3-day bladder diary, King’s Health Questionnaire and collect self-reported data on adherence and adverse events. Acceptability of using TTNS will be evaluated at the end of intervention. This study has been reviewed and approved by the Education and Health Science’s Faculty Research Ethics Committee, University of Limerick [2020_06_07_EHS].  Conclusion: It is anticipated that assessing the feasibility and acceptability of TTNS for storage bladder symptoms in MS will inform the development of a definitive randomised trial. Trial registration: ClinicalTrials.gov NCT04528784 27/08/2020


2013 ◽  
Vol 189 (4S) ◽  
Author(s):  
Silvia Proietti ◽  
Marilena Gubbiotti ◽  
Jacopo Adolfo Rossi de Vermandois ◽  
Massimo Porena ◽  
Antonella Giannantoni

2015 ◽  
Vol 7 (1) ◽  
pp. 52-58 ◽  
Author(s):  
Tatsuya Yamamoto ◽  
Masahiro Mori ◽  
Akiyuki Uzawa ◽  
Tomoyuki Uchiyama ◽  
Ryuji Sakakibara ◽  
...  

BMJ ◽  
1965 ◽  
Vol 1 (5445) ◽  
pp. 1265-1269 ◽  
Author(s):  
H. Miller ◽  
C. A. Simpson ◽  
W. K. Yeates

Sign in / Sign up

Export Citation Format

Share Document